Experiments that remove senescent cells or change the signals they release.
The programme must establish which cells were affected and what changed in the tissue.
Each dossier describes the mechanism, studies and development history of a research programme.
3 programmes and 1 article in this edition.
UNITY Biotechnology
UNITY tested a senolytic eye injection against an established treatment for diabetic macular oedema. ASPIRE missed its prespecified primary comparison. A later analysis reported noninferiority at week 36. UNITY subsequently closed its operating business.
Mayo-origin senolytic research and collaborating academic groups
Academic groups are testing whether a drug combination can remove senescent cells and improve particular diseases. Human results include tissue-marker changes, a negative primary bone endpoint and a small positive liver-fibrosis trial. These are distinct experiments with different populations and outcomes.
Academic collaborations at Memorial Sloan Kettering and Cold Spring Harbor Laboratory
Researchers have engineered T cells to recognise uPAR, a surface protein associated with senescence. Mouse studies test whether clearing these cells improves metabolism and intestinal function.
UBX0101 failed its prespecified pain endpoint in a 183-participant knee osteoarthritis trial. Development stopped. The result does not establish why the treatment failed.
Read article